Chronic low-grade inflammation in adipose tissue often accompanies obesity, leading to insulin resistance and increasing the risk for metabolic diseases. MAP3K8 (TPL2/COT) is an important signal transductor and activator of pro-inflammatory pathways that has been linked to obesity-induced adipose tissue inflammation. We used human adipose tissue biopsies to study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1β, IL-6 and IL-8). Moreover, we evaluated obesity-induced adipose tissue inflammation and insulin resistance in mice lacking MAP3K8 and WT mice on a high-fat diet (HFD) for 16 weeks. Individuals with a BMI >30 displayed a higher mRNA expression of MAP3K8 in adipose tissue compared to individuals with a normal BMI. Additionally, high mRNA expression levels of IL-1β, IL-6 and IL-8, but not TNF -α, in human adipose tissue were associated with higher expression of MAP3K8. Moreover, high plasma SAA and CRP did not associate with increased MAP3K8 expression in adipose tissue. Similarly, no association was found for MAP3K8 expression with plasma insulin or glucose levels. Mice lacking MAP3K8 had similar bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1β, IL-6 and CXCL1 in adipose tissue in response to the HFD as compared to WT animals. However, MAP3K8 deficient mice were not protected against HFD-induced adipose tissue macrophage infiltration or the development of insulin resistance. Together, the data in both human and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1β and its responsive cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance.
References
[1]
Gregor MF, Hotamisligil GS (2011) Inflammatory Mechanisms in Obesity. Annu Rev Immunol.
[2]
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98–107. doi: 10.1038/nri2925
[3]
Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246. doi: 10.1146/annurev-physiol-021909-135846
[4]
Tanti JF, Jager J (2009) Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 9: 753–762. doi: 10.1016/j.coph.2009.07.004
[5]
Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF (2007) Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148: 241–251. doi: 10.1210/en.2006-0692
[6]
Bost F, Aouadi M, Caron L, Even P, Belmonte N, et al. (2005) The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54: 402–411. doi: 10.2337/diabetes.54.2.402
[7]
Chiariello M, Marinissen MJ, Gutkind JS (2000) Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 20: 1747–1758. doi: 10.1128/mcb.20.5.1747-1758.2000
[8]
Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, et al. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J 15: 817–826.
[9]
Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071–1083. doi: 10.1016/s0092-8674(00)00210-5
[10]
Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, et al. (2010) Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 59: 61–70. doi: 10.2337/db09-0470
[11]
Perfield JW 2nd, Lee Y, Shulman GI, Samuel VT, Jurczak MJ, et al. (2011) Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance. Diabetes 60: 1168–1176. doi: 10.2337/db10-0715
[12]
Lancaster GI, Kowalski GM, Estevez E, Kraakman MJ, Grigoriadis G, et al. (2012) Tumor progression locus 2 (Tpl2) deficiency does not protect against obesity-induced metabolic disease. PLoS One 7: e39100. doi: 10.1371/journal.pone.0039100
[13]
Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, et al. (2004) A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J Clin Invest 114: 857–866. doi: 10.1172/jci200420014
[14]
Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG (2011) Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 304: 80–89. doi: 10.1016/j.canlet.2011.02.004
[15]
Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, et al. (2009) Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol 183: 7984–7993. doi: 10.4049/jimmunol.0901336
[16]
Gantke T, Sriskantharajah S, Ley SC (2011) Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 21: 131–145. doi: 10.1038/cr.2010.173
[17]
Raman M, Chen W, Cobb MH (2007) Differential regulation and properties of MAPKs. Oncogene 26: 3100–3112. doi: 10.1038/sj.onc.1210392
[18]
Dinarello CA (2010) How interleukin-1beta induces gouty arthritis. Arthritis Rheum 62: 3140–3144. doi: 10.1002/art.27663
[19]
Chassaing B, Aitken JD, Gewirtz AT, Vijay-Kumar M (2012) Gut microbiota drives metabolic disease in immunologically altered mice. Adv Immunol 116: 93–112. doi: 10.1016/b978-0-12-394300-2.00003-x
